Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares OutstandingShares OutstandingShares Repurchased
Ratios

Cross Country Healthcare (CCRN) Accumulated Depreciation & Amortization (2016 - 2025)

Cross Country Healthcare's Accumulated Depreciation & Amortization history spans 15 years, with the latest figure at $16.8 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization fell 7.73% year-over-year to $16.8 million; the TTM value through Dec 2025 reached $16.8 million, down 7.73%, while the annual FY2025 figure was $16.8 million, 7.73% down from the prior year.
  • Accumulated Depreciation & Amortization reached $16.8 million in Q4 2025 per CCRN's latest filing, up from $13.0 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $18.3 million in Q4 2023 to a low of $2.3 million in Q1 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $8.1 million, with a median of $5.6 million recorded in 2022.
  • The largest YoY upside for Accumulated Depreciation & Amortization was 188.15% in 2025 against a maximum downside of 56.19% in 2025.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $9.9 million in 2021, then grew by 27.65% to $12.6 million in 2022, then soared by 45.89% to $18.3 million in 2023, then fell by 0.8% to $18.2 million in 2024, then decreased by 7.73% to $16.8 million in 2025.
  • Per Business Quant, the three most recent readings for CCRN's Accumulated Depreciation & Amortization are $16.8 million (Q4 2025), $13.0 million (Q3 2025), and $4.1 million (Q2 2025).